Biotechnology Etf Profile

FBT -  USA Etf  

USD 145.08  4.68  3.33%

Market Performance
0 of 100
Odds Of Distress
Less than 1
Biotechnology Index is selling for under 145.08 as of the 29th of January 2022; that is 3.33% increase since the beginning of the trading day. The etf's last reported lowest price was 139.2. Biotechnology Index has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Biotechnology Index NYSE are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of February 2020 and ending today, the 29th of January 2022. Click here to learn more.
The investment seeks investment results that correspond generally to the price and yield of an equity index called the NYSE Arca Biotechnology IndexSM. Biotechnology Index is traded on NYSEArca Exchange in the United States.. More on Biotechnology Index NYSE

Biotechnology Index Etf Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Biotechnology Index's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Biotechnology Index or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Biotechnology Index generated a negative expected return over the last 90 days
Biotechnology Index is unlikely to experience financial distress in the next 2 years
The fund retains 99.94% of its assets under management (AUM) in equities
Legal NameBiotechnology Index NYSE
ChairmanJames Bowen  (View All)
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Biotechnology Index's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
IssuerFirst Trust
DescriptionFirst Trust NYSE Arca Biotechnology Index Fund
Inception Date2006-06-19
BenchmarkNYSE Arca Biotechnology Index
Entity TypeRegulated Investment Company
Asset Under Management1.52 Billion
Average Trading Valume63,504.1
Asset TypeEquity
FocusHealth Care
Market ConcentrationDeveloped Markets
RegionNorth America
AdministratorThe Bank of New York Mellon Corporation
AdvisorFirst Trust Advisors L.P.
CustodianThe Bank of New York Mellon Corporation
DistributorFirst Trust Portfolios L.P.
Portfolio ManagerDaniel J. Lindquist, Jon C. Erickson, David G. McGarel, Roger F. Testin, Stan Ueland, Chris A. Peterson
Transfer AgentThe Bank of New York Mellon Corporation
Fiscal Year End30-Jun
ExchangeNYSE Arca, Inc.
Market MakerRBC Capital Markets
Total Expense0.55
Management Fee0.4
Nav Price158.37
Two Hundred Day Average165.08
Average Daily Volume In Three Month48.96k
Trailing Annual Dividend Rate0.02
Fifty Two Week Low138.6
As Of Date31st of August 2021
Trailing Annual Dividend Yield0.01%
Average Daily Volume Last 10 Day70.22k
Fifty Two Week High186.51
One Month3.53%
Fifty Day Average157.61
Biotechnology Index NYSE [FBT] is traded in USA and was established 2006-06-19. The fund is classified under Health category within First Trust family. Biotechnology Index NYSE currently have 1.93 B in assets under management (AUM). , while the total return for the last 3 years was 3.4%.
Check Biotechnology Index Probability Of Bankruptcy

Top Biotechnology Index NYSE Constituents

Biotechnology Index Target Price Odds Analysis

What are Biotechnology Index's target price odds to finish over the current price? Attributed to a normal probability distribution, the odds of Biotechnology Index jumping above the current price in 90 days from now is roughly 97.0%. The Biotechnology Index NYSE probability density function shows the probability of Biotechnology Index etf to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon Biotechnology Index has a beta of 0.5635. This usually indicates as returns on the market go up, Biotechnology Index average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Biotechnology Index NYSE will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Biotechnology Index NYSE is significantly underperforming DOW.
 Odds Down 145.08HorizonTargetOdds Up 145.08 
3.04%90 days
Based on a normal probability distribution, the odds of Biotechnology Index to move above the current price in 90 days from now is roughly 97.0 (This Biotechnology Index NYSE probability density function shows the probability of Biotechnology Etf to fall within a particular range of prices over 90 days) .

Biotechnology Index Top Holders

Biotechnology Index Major Institutional Holders

Institutional Holdings refers to the ownership stake in Biotechnology Index that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Biotechnology Index's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Biotechnology Index's value.
InstituionSecurity TypeTotal SharesValue
Berger Financial Group IncFund Units125 K20.2 M
View Biotechnology Index Diagnostics

Biotechnology Index NYSE Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Biotechnology Index market risk premium is the additional return an investor will receive from holding Biotechnology Index long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Biotechnology Index. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Biotechnology Index's alpha and beta are two of the key measurements used to evaluate Biotechnology Index's performance over the market, the standard measures of volatility play an important role as well.

Biotechnology Index NYSE Technical Analysis

The output start index for this execution was zero with a total number of output elements of sixty-one. Biotechnology Index NYSE Sinh Values Of Price Series is a hyperbolic price transformation function. View also all equity analysis or get more info about sinh values of price series math transform indicator.

Biotechnology Index Against Markets

Picking the right benchmark for Biotechnology Index etf is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Biotechnology Index etf price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Biotechnology Index is critical whether you are bullish or bearish towards Biotechnology Index NYSE at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Biotechnology Index without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Fundamentals Comparison Now


Fundamentals Comparison

Compare fundamentals across multiple equities to find investing opportunities
All  Next Launch Module
Please check Investing Opportunities. Note that the Biotechnology Index NYSE information on this page should be used as a complementary analysis to other Biotechnology Index's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Transformation module to use Price Transformation models to analyze depth of different equity instruments across global markets.

Complementary Tools for Biotechnology Etf analysis

When running Biotechnology Index NYSE price analysis, check to measure Biotechnology Index's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotechnology Index is operating at the current time. Most of Biotechnology Index's value examination focuses on studying past and present price action to predict the probability of Biotechnology Index's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Biotechnology Index's price. Additionally, you may evaluate how the addition of Biotechnology Index to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
The market value of Biotechnology Index NYSE is measured differently than its book value, which is the value of Biotechnology that is recorded on the company's balance sheet. Investors also form their own opinion of Biotechnology Index's value that differs from its market value or its book value, called intrinsic value, which is Biotechnology Index's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biotechnology Index's market value can be influenced by many factors that don't directly affect Biotechnology Index's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biotechnology Index's value and its price as these two are different measures arrived at by different means. Investors typically determine Biotechnology Index value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biotechnology Index's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.